The Science of Thermoregulation and Vasomotor Symptoms: Possible New Targets for

体温调节和血管舒缩症状的科学：可能的新目标

• 批准号: 8784849
• 负责人: PAULINE M MAKI
• 金额: $ 4.64万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-15 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8784849
• 关键词: Address; Aging; American; Antidepressive Agents; Area; Award; Basic Science; Cancer Survivor; Cardiovascular system; Clinical; Clinical Research; Cognitive; Complementary and alternative medicine; Consensus; Data; Development; District of Columbia; Dose; Etiology; Exercise; Exercise Physiology; FDA approved; Funding; Goals; Health; Homeostasis; Hot flushes; Journals; Knowledge; Link; Medical; Medicine; Menopausal Symptom; Menopause; Meta-Analysis; National Institute on Aging; Neurobiology; Neuropharmacology; Night Sweating; North America; Omega-3 Fatty Acids; Oral; Outcome; Paroxetine; Participant; Pathway interactions; Pharmaceutical Preparations; Physiologic Thermoregulation; Physiology; Professional Organizations; Publications; Publishing; Quality of life; Randomized Clinical Trials; Recommendation; Research; Research Personnel; Research Priority; Resources; Science; Scientific Advances and Accomplishments; Scientist; Secure; Selective Serotonin Reuptake Inhibitor; Seminal; Skin; Societies; Staging; Symptoms; Temperature; Travel; United States National Institutes of Health; Vasomotor; Woman; Women' s Health; Work; Yoga; base; clinical efficacy; cognitive function; depressive symptoms; drug development; experience; healthy aging; hormone therapy; innovation; meetings; middle age; multidisciplinary; neuroimaging; neurophysiology; new therapeutic target; posters; pre-clinical research; programs; public health relevance; randomized trial; reproductive; standard care; success; symposium; web site; working group

DESCRIPTION (provided by applicant): More than 80% of women experience vasomotor symptoms (VMS; hot flashes and night sweats) during the menopausal transition. The use of hormone therapy, the standard treatment for VMS, decreased by 75% after publication of the findings from the Women's Health Initiative. The only FDA-approved nonhormonal treatment for VMS is paroxetine, a low-dose antidepressant that showed significant but modest efficacy in randomized trials. In the past decade, our understanding of the efficacy of nonhormonal therapies on VMS has increased considerably based on findings from randomized clinical trials. Unfortunately, the results from these trials show no-to-minimal efficacy, and two nonhormonal VMS medications recently failed to win FDA approval. Women therefore have very few nonhormonal treatment options for VMS. To address the continuing need for development of new nonhormonal therapies for VMS, we propose a multidisciplinary, 2-day conference, The Science of Thermoregulation and Vasomotor Symptoms: Possible New Targets for Treatment. The conference will convene a diverse group of 20 to 25 basic and clinical researchers as well as clinicians to discuss normal and aberrant thermoregulation, the neurophysiology of VMS, and new potential treatment targets. The aim of the conference is to facilitate synthesis and exchange of new data by promoting scientific exchange among experts who do not typically interact scientifically but whose work informs the others. In recent years, scientific understanding of the mechanisms involved in VMS has evolved considerably based on findings from basic science, physiology, neuroimaging, and studies of skin dynamics. The specific aims are to 1) describe current understanding of the physiology and neuropharmacology of thermoregulation and VMS; 2) describe current understanding of nonhormonal treatments for VMS; 3) review existing evidence from studies linking VMS to adverse health outcomes in women, including quality of life, cardiovascular outcomes, and cognitive function; 4) integrate new and emerging data from multiple areas of inquiry into an initial conceptual framework to better understand the causal pathway of VMS and potential avenues for new drug development. The Day 1 public symposium, open to 80 participants, will feature oral and poster presentations of recent scientific advances in thermoregulation and VMS and discussion of the implications of this new evidence for the development of nonhormonal VMS treatments. On Day 2, facilitated working groups will discuss and respond to targeted questions regarding research priorities. We offer four travel awards for new investigators. The meeting will be sponsored by The North American Menopause Society (NAMS) and will take place October 14-15, 2014, just before the 25th NAMS Annual Meeting in Washington, DC. The symposium recommendations will be presented in a special session at the NAMS meeting. A Program Planning Committee will prepare a conference summary for oral presentation at the NAMS Annual Meeting, an executive summary of the recommendations for publication in the official NAMS journal, Menopause, and a lay version to be published on the NAMS website.

描述(申请人提供)：超过80%的女性在更年期过渡期间出现血管舒缩症状(VMS；潮热和盗汗)。在妇女健康倡议的研究结果公布后，激素疗法的使用减少了75%，这是VMS的标准治疗方法。FDA批准的唯一治疗VMS的非激素疗法是帕罗西汀，这是一种低剂量的抗抑郁药，在随机试验中显示出显著但不大的疗效。在过去的十年中，基于随机临床试验的结果，我们对非激素疗法治疗VMS的疗效的了解有了很大的提高。不幸的是，这些试验的结果显示没有或只有很小的疗效，最近两种非激素VMS药物未能获得FDA的批准。因此，女性对于VMS的非激素治疗选择很少。为了应对VMS新的非激素疗法的持续开发需求，我们建议召开一个为期两天的多学科会议，名为体温调节和血管运动症状的科学：可能的新治疗靶点。会议将召集由20至25名基础和临床研究人员以及临床医生组成的不同小组，讨论正常和异常体温调节、VMS的神经生理学以及新的潜在治疗目标。会议的目的是通过促进专家之间的科学交流，促进新数据的合成和交流，这些专家通常不进行科学互动，但其工作为其他专家提供信息。近年来，在基础科学、生理学、神经成像和皮肤动力学研究的基础上，对VMS涉及的机制的科学理解有了很大的发展。具体目标是1)描述体温调节和VMS的生理学和神经药理学的当前了解；2)描述VMS的非激素治疗的当前理解；3)综述VMS与女性不良健康结局(包括生活质量、心血管结果和认知功能)之间的研究的现有证据；4)将来自多个调查领域的新的和新兴的数据整合到一个初步的概念框架中，以更好地了解VMS的致病途径和新药开发的潜在途径。第一天的公开研讨会向80名与会者开放，将以口头和海报形式介绍体温调节和VMS方面的最新科学进展，并讨论这一新证据对开发非激素VMS治疗的影响。在第二天，促进工作组将讨论并回答有关研究优先事项的有针对性的问题。我们为新调查人员提供四个旅行奖励。这次会议将由北美更年期协会(NAMS)赞助，将于2014年10月14日至15日在华盛顿举行第25届NAMS年会之前举行。专题讨论会的建议将在不结盟运动会议的特别会议上提出。方案规划委员会将准备一份会议摘要，供在全国妇女协会年会上口头陈述，一份建议的执行摘要，供在全国妇女协会官方期刊《更年期》上发表，以及一份将在全国妇女协会网站上发表的非专业版本。